Vanucizumab

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1].

Product Specifications

CAS Number

[1448221-05-3]

Product Name Alternative

Anti-Human VEGFA Recombinant Antibody; RO5520985

UNSPSC

12352203

Target

Tie; VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vanucizumab.html

Purity

95.12

Solubility

10 mM in DMSO

Smiles

[Vanucizumab]

Molecular Weight

(146.89 kDa)

References & Citations

[1]Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24 (7) :1536-1545.|[2]Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108 (27) :11187-92.